BPC-157
Status unknownAlso known as: 137525-51-0, Bpc 157, Bepecin, Bpc 15, L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-, pl-10, 8ED8NXK95P, PLD-116
BPC-157 (137525-51-0, Bpc 157, Bepecin) is classified under repair & thymosin peptides.
What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
BPC-157 (body protection compound-157) is described as a stable gastric pentadecapeptide that has been investigated largely in preclinical models for effects related to cytoprotection and tissue repair across multiple organ systems, including musculoskeletal soft tissue and bone injuries. A systematic review from an orthopedic sports medicine perspective identified 36 included studies (35 preclinical, 1 clinical) reporting musculoskeletal improvements in multiple injury types, along with liver metabolism and kidney clearance; it also reported that no clinical safety data were found. (PMIDs: 40756949)
Mechanism (as reported)
Research reports that BPC-157 has been associated with effects on growth hormone receptor expression, pathways related to cell growth and angiogenesis, and reduced inflammatory cytokines in preclinical literature. (PMID: 40756949) Additional review material describes involvement of multiple molecular pathways in reported cytoprotective effects (including modulation of NO-system components and prostaglandin system effects) and activation of collateral pathways in vascular/ischemia-reperfusion contexts in animal studies. (PMID: 36359218) Another review describes gene-expression increases in rat excision skin wound as part of wound-healing research. (PMID: 34267654)
Key findings (each cites a source)
- A systematic review reported that, across 35 preclinical studies and 1 clinical study, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injury models. (PMID: 40756949) [PMID 40756949]
- The systematic review reported that the studies suggested BPC-157 enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis, and reduces inflammatory cytokines. (PMID: 40756949) [PMID 40756949]
- The systematic review reported liver metabolism with a half-life of less than 30 minutes and clearance by the kidneys. (PMID: 40756949) [PMID 40756949]
- The systematic review reported that preclinical safety studies showed no adverse effects across several organ systems and that no clinical safety data were found. (PMID: 40756949) [PMID 40756949]
- A retrospective chart review reported that, among 12 patients receiving intra-articular BPC-157 alone for knee pain, 11 reported significant improvement and 1 reported no improvement; among 4 patients receiving BPC-157 combined with thymosin-beta-4, 75% showed significant improvement and 25% had no relief; overall, 14 of 16 reported relief. (PMID: 40005999) [PMID 40005999]
- A narrative/biopharmaceutical review reported that no approved formulation and no validated dosing regimen were available, and that there were no completed Phase II clinical trials; it also described a disconnect between short plasma half-life reported in preclinical contexts and longer biological effects reported in the overall literature. (PMID: 42198317) [PMID 42198317]
- A narrative review of wound healing described that BPC-157 was reviewed as effective in skin wound healing in rat studies, with reported involvement in resolution of vessel constriction, platelet plug and fibrin mesh, and clot resolution. (PMID: 34267654) [PMID 34267654]
- An additional review described an 'angiogenic effect' in healing models, stating that BPC-157 was consistently effective across multiple gastrointestinal tract injury models and that it improved tendon, ligament, and bone healing in the context of review comparisons. (PMID: 29998800) [PMID 29998800]
Independent test grades (86 vendors)
Aggregated from Finnrick (independent testing). Their grades, attributed — not our verdict.
| Vendor | Grade | Score |
|---|---|---|
| Great Basin Bio Supply | A | 8.5 |
| HkRoids | A | 8.3 |
| Rhome Research | A | 8.1 |
| Precision Peptide Co | B | 8.1 |
| Yabang Peptide | A | 8.1 |
| Andy Peps Studio | B | 8.1 |
| Bulk Peptide Wholesale | A | 8.0 |
| LiliPeptide | C | 8.0 |
| Peptide Sciences | A | 7.8 |
| Shanghai ERP peptide Biotechnology | B | 7.7 |
| Peptide Technologies | B | 7.7 |
| Peptide Partners | B | 7.7 |
| Peptime | A | 7.5 |
| Shanghai Baoju | C | 7.5 |
| Uther | C | 7.4 |
| PurePEPS | B | 7.3 |
| Suaway Lab Research | A | 7.3 |
| Coffee and Peppers | A | 7.2 |
| Welon Peptide Solutions | B | 7.2 |
| Forever Young Pharmacy | B | 7.2 |
| Yiwu Aozuo Trading Co | E | 7.1 |
| Pure Rawz | C | 7.1 |
| Nexaph | E | 7.1 |
| Eternal Peptides | C | 7.1 |
| Atomik Labz | B | 7.0 |
Research literature (8)
Consolidated from PubMed — each links to the original record.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R · Pharmaceutics · 2026 · PMID 42198317
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40005999
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · PMID 40756949
- Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation.
Sikiric P, Udovicic M, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D · Biomedicines · 2022 · PMID 36359218
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB · Frontiers in pharmacology · 2021 · PMID 34267654
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett B · Alternative therapies in health and medicine · 2021 · PMID 34324435
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Gwyer D, Wragg NM, Wilson SL · Cell and tissue research · 2019 · PMID 30915550
- BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.
Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B · Current pharmaceutical design · 2018 · PMID 29998800
FAQ
- What is BPC-157?
- BPC-157 (137525-51-0, Bpc 157, Bepecin) is classified under repair & thymosin peptides. Research goals associated with it include recovery & tissue repair.
- Is BPC-157 FDA-approved?
- The regulatory status of BPC-157 is not established in our sources.
- What does the research on BPC-157 say?
- peptideone aggregates 8 references from PubMed for BPC-157. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.